Q-omics provides the consensus-scored MT-TS1 profile across patient tissues and cancer cell-line models. MT-TS1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MT-TS1 is differentially expressed in 2, with the highest sampling consensus in BLCA. Additionally, MT-TS1 RNA expression shows 6,614 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CESC, BLCA, and KIRP as cancer lineages where MT-TS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-TS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-TS1 survival associations across molecular data types. MT-TS1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-TS1 RNA expression–survival associations across cancer types. High MT-TS1 expression shows unfavorable associations in CESC, ESCA, SKCM, LUAD, TGCT and COAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .013). Together, the overview and detailed table identify CESC as the clearest survival context for MT-TS1 RNA expression.
This table summarizes MT-TS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MT-TS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-TS1 shows lower tumor expression in BLCA and higher tumor expression in THCA. The BLCA box plot shows higher MT-TS1 RNA expression in normal versus tumor tissue (log2 FC = −0.186, t-test p = .036).
This table shows molecular features associated with MT-TS1 in patient tissues and cancer cell lines. In patient samples, MT-TS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
